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Previewsthat increases in HIF-1a levels were asso-
ciated with an increase in pyruvate dehy-
drogenase kinase 1 levels, which would
be expected to inhibit glucose oxidation,
since this kinase phosphorylates and
inhibits the rate-limiting enzyme for
glucose oxidation, pyruvate dehydroge-
nase. These results suggest that the
Adora2b and Per2 signaling pathway,
while increasing glycolysis, may actually
impair glucose oxidation (Figure 1), as
Per 2 deletion appears to enhance
glucose oxidation. How the increase in
glycolysis together with the probable
decrease in glucose oxidation affects
cardiac function during reperfusion
following ischemia will require further
clarification.
The effects of adenosine and adeno-
sine receptor activation on cardiac glu-
cose metabolism have been extensively
studied. Activation of either adenosine
receptor, Adora1 or Adora2, provides
cardioprotection. Yet, Adora1, unlike
Adora2, decreases glycolytic rates in the4 Cell Metabolism 16, July 3, 2012 ª2012 Elsheart and improves coupling between
glycolysis and glucose oxidation (Finegan
et al., 1996). On the surface, these results
appear to be at odds with the cardiopro-
tection observed with Adora2b stimula-
tion, which, as shown by Eckle et al.
(2012), promotes glycolysis in the heart.
As such, further studies are necessary to
examine the relationship between adeno-
sine receptor signaling, glucose metabo-
lism, and cardioprotection. Nevertheless,
the involvement of Per2 and HIF-1a, and
the potential circadian rhythm of this
pathway provide important insights into
the control of glycolysis, and the potential
role of these changes in adaptation to
myocardial ischemia.
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A recent study (Cipolletta et al., 2012) shows that regulatory T (Treg) cells expressing the peroxisome-prolif-
erator- activated receptor (PPAR-g) are engaged in suppressing adipose tissue inflammation in obesity, sug-
gesting that Treg cells may be a target for treatment and prevention of adipose tissue inflammation and
insulin resistance.In obesity, enlarged adipocytes accumu-
lating in visceral adipose tissue (VAT) elicit
infiltration of macrophages and other
immune cells (Feuerer et al., 2009, Winer
et al., 2009, Nishimura et al., 2009,Olefsky
and Glass, 2010). These cells secrete
proinflammatory cytokines and mediate
chronic low-grade inflammation in VAT.
The inflamed adipose tissue, in turn, may
release cytokines, adipokines, fatty acids,
and other substances that may affectother organs, such as liver and muscle,
leading to systemic insulin resistance. A
recent study from Cipolletta and
colleagues reveals an important role for
VAT-specific natural Treg cells in the
suppressionof obesity-associated inflam-
mation in VAT and consequently in
combatting insulin resistance (Cipolletta
et al., 2012).
Naturally occurring Treg cells are a
unique CD4+ T cell subpopulation specifi-cally adapted to the suppression of
aberrant or excessive immune responses
that are harmful to the host (Sakaguchi
et al., 2008). In physiological conditions,
they constitute 10% of peripheral CD4+
Tcellsandarecharacterizedby theexpres-
sion of the transcription factor Foxp3. The
majority of Foxp3+ CD4+ Treg cells are
produced by the thymus as a functionally
mature and distinct T cell subpopulation,
although naive conventional T cells can
Figure 1. Foxp3+ Treg Cells Expressing Specific Nuclear Factors
Control Different Types of Inflammation
Foxp3+ Treg cells produced by the thymus or having developed from naive
T cells further differentiate in response to distinct inflammatory signals to effec-
tively control particular types of inflammation. For example, Foxp3+ Tregs cells
expressing T-bet, a transcription factor that specifically controls Th1 cell differ-
entiation and function, are abundant in type 1 inflammation sites. Similarly,
Foxp3+ Treg cells expressing GATA3 or STAT3 are enriched in sites of inflam-
mationmediatedbyTh2orTh17cells, respectively. Thesedifferent transcription
factors interactwith Foxp3 in Treg cells and thereby specifically control each Th
cell type. Indeed,Treg-specificdeletionof thesemolecules impairs Treg’sability
to control respective types of inflammation (Josefowicz et al., 2012). Similarly,
a subset of Foxp3+ Treg cells expressing PPARg accumulate in VAT during
low-grade inflammation and suppress the activity of other immune cells
including inflammatory macrophages and monocytes (Cipolletta et al., 2012).
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Previewsalso differentiate into Foxp3+
Tregcells under certain condi-
tions. The key role of Foxp3+
Tregcells in immune tolerance
and homeostasis is best illus-
trated by Foxp3 gene muta-




type 1 diabetes mellitus,
allergy, and inflammatory
bowel disease in humans (Sa-
kaguchi et al., 2008). Foxp3+
Treg cells are involved in
suppressive control of almost
any physiological and patho-
logical immune response and
inflammation at any site.
Indeed, they exhibit suppres-
siveactivity in an inflammation
type-dependentmanner, con-
trolling specific types of
T cells, such as Th1, Th2, and
Th17 (Josefowicz et al., 2012)
(Figure 1). Foxp3+ Treg cells
are abundant in VAT and
have a different T cell receptor
repertoire compared with
Treg cells in other tissues,
suggesting that they might be
activated via the recognition
of a fat tissue-specific antigen
(Feuerer et al., 2009). The
number of VAT Treg cells is
strikingly and specifically
reduced in insulin-resistant




show that these VAT-resident
Foxp3+ Tregs specifically
express the peroxisome pro-
liferator-activated receptor(PPAR)g (Cipolletta et al., 2012), a nuclear
receptor that is required for adipocyte
development and is also the target for
the insulin-sensitizing drugs thiazolidine-
diones (TZDs) (Spiegelman, 1998).
PPARg appears to interact with Foxp3 in
VAT-Treg cells. Indeed, ectopic coex-
pression of Foxp3 and PPARg in conven-
tional T cells induces a VAT-Treg type
gene-expression profile. Specifically,
two variants of PPARg, PPARg1 and 2,
both promote upregulation of VAT-Treg
genes, but only PPARg1 induces repres-
sion of VAT-Treg genes.Cipolletta et al. (2012) further investi-
gate the role of PPARg expression in
VAT-Treg by the use of Foxp3-dependent
PPARgconditional knockout mice. This
Treg cell-specific deletion of PPARg
reduces the number of Treg cells specifi-
cally in VAT, resulting in an increase in
VAT infiltration by proinflammatory mac-
rophages and monocytes. Interestingly,
PPARg stimulation by pioglitazone, a
TZD drug, specifically increases Treg
cell numbers in the VAT of obese mice
fed a high-fat diet, leading to a concomi-
tant improvement in insulin sensitivity.Cell Metabolism 16, JulyThese results collectively indi-
cate that PPARg-expressing
Foxp3+ Treg cells play
a unique role in suppressing
VAT inflammation caused by
overnutrition, and that TZDs
may enhance insulin sensi-
tivity, at least in part, through
increasing PPARg-express-
ing Foxp3+ Treg cells in VAT.
These findings on VAT-resi-
dent PPARg-expressing Treg
cells raise several key issues
for future research. First,
what is the role of PPARg for
VAT Treg cell function? Given
that PPARg is regulated by
free fatty acids and their
metabolites (Chawla et al.,
2001), Treg cells may sense
these substances, as a result,
express PPARg and migrate
to the adipose tissue releasing
the substances. Alternatively,
it is also possible that Treg
cells recruited to VAT inflam-
mation sites via chemokine or
the recognition of a tissue-
specific antigen may express
PPARg in response to local
signals. PPARg is also ex-
pressed by macrophages as
a negative regulator of intra-
cellular macrophage inflam-
matory pathways, possibly
resulting in their conversion
fromM1macrophages, which
are proinflammatory, to the
anti-inflammatory M2 type
(Olefsky and Glass, 2010).
Thus, PPARg-expressing
Treg cells and macrophages
might cooperatively con-
tribute to suppressing
obesity-associated VATinflammation. TZDs may act on both
Treg cells and macrophages, restoring
insulin sensitivity.
Second, how do the Treg cells control
inflammation in VAT? They secrete a high
amount of IL-10, an anti-inflammatory
cytokine, as observed with Foxp3 Treg
cells in the intestinal mucosa, where Treg
cells appear to be continually activated
by intestinal commensal bacteria. It
remains to be determined whether
Foxp3+ Treg cells primarily control
effector T cells (Winer et al., 2009; Nishi-
mura et al., 2009), which then activate3, 2012 ª2012 Elsevier Inc. 5
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Previewsmacrophages, or directly control macro-
phages, at least in part via secretion of
IL-10. Augmentation of such suppressive
activities of PPARg-expressing Treg cells
may enable better control of VAT inflam-
mation in obesity.
Lastly, are Treg cells involved in other
chronic low-grade inflammation accom-
panying tissue damage? In atheroscle-
rosis, for example, Foxp3+ Treg cells
present in atheroma lesions have been
implicated in suppressing the formation
of foam cells from macrophages (Ait-Ou-
fella et al., 2006). Pioglitazone has
a protective effect on atherosclerosis.
The effect of pioglitazone in VAT, causing
an increase in VAT Treg cells, suggests
that a similar mechanism may underlie
theprotective effects of thedrug in athero-
sclerosis. Further investigation is required
to determine the possible contribution of6 Cell Metabolism 16, July 3, 2012 ª2012 ElsFoxp3+ Treg cells to the control of other
chronic immunometabolic diseases, in
which targeting tissue-specific Foxp3+
Tregcells could represent anewapproach
for treatment and prevention.
In conclusion, the finding by Cipolletta
et al. (2012) on the presence of VAT-resi-
dent PPARg-expressing Treg cells that
control VAT inflammation in obesity
provides a new link between immunoreg-
ulation and metabolic disease, and may
be exploited to devise immunotherapies
for immunometabolic diseases.
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Reducing caloric intake, while maintaining adequate nutrition, promotes longevity in diverse organisms,
possibly by preserving stem and progenitor cell function. Yilmaz and colleagues (2012) now show that caloric
restriction alters intestinal stem cell proliferation and differentiation, and elucidate a mechanism for how the
mammalian stem cell niche responds to environmental inputs.Intestinal stem cells (ISCs) can self-
renew and differentiate for the life of the
organism. Residing in the crypts of
Lieberku¨hn, intestinal stem cells give rise
to transit-amplifying cells, which pro-
liferate and differentiate into cell types
that populate the intestine. Enterocytes,
goblet, and enteroendocrine cells are
found in villi, whereas Paneth cells are
found at the base of the crypts inter-
spersed with the stem cells. Paneth cells
have been implicated in providing essen-
tial paracrine factors including Wnt and
Notch and acting as an essential stemcell niche (Sato et al., 2011). Ex vivo
cultures of crypt cells can be used to
model formation of the intestine. These
organoid cultures have implicated Paneth
cells as essential for stem cell differentia-
tion, and some models of Paneth cell loss
suggest that Paneth cells are required
for intestinal development. However, the
assumption that Paneth cells are required
for the integrity of stem cells and organoid
formation has been questioned by two
recent papers (Durand et al., 2012; Kim
et al., 2012). These studies demonstrated
that complete loss of Paneth cells doesnot prevent the ability of stem cells to
proliferate, differentiate, and fully recon-
stitute the villus in vivo. Organoid forma-
tion was still largely dependent on the
presence of Paneth cells, although this
could be partially rescued by supplemen-
tation with Wnt ligands (Durand et al.,
2012). In the latest in a series of develop-
ments regarding the role of Paneth cells in
the regulation of intestinal stem cells,
Yilmaz et al. (2012) show that Paneth cells
mediate the effects of calorie restriction
on intestinal stem cells. They show that
reduction in caloric intake inhibits the
